 ENGLEWOOD, Colo., July 28, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Companys abstract presentation, Significant Inhibition of the TLR7CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and Lupus Nephritis, being given virtually at the 14th International Congress on Systemic Lupus Erythematosus LUPUS 2021 6th International Congress on Controversies in Rheumatology and Autoimmunity CORA on October 6-9, 2021. 